Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risvutatug rezetecan (GSK5764227) in Advanced Solid Tumors
NCT06551142Phase 1Recruiting
- Sponsor
- GSK
- Start
- Sep 2024
- Primary completion
- Oct 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 13
01
Overview
Phase 1, open-label trial of risvutatug rezetecan in solid tumor (6 arms), sponsored by GSK. Primary endpoints: Number of participants with Adverse Events at 28 months, Number of participants with Dose Limiting Toxicities at 21 days and 4 more. Started Sep 2024; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06551142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551142.